Action of serotonin (5-hydroxytryptamine) on cyclic nucleotides in glomeruli of rat renal cortex  by Shah, Sudhir V. et al.
Kidney International, Vol. 15 (1979), pp. 463 -4 72
Action of serotonin (5-hydroxytryptamine) on cyclic
nucleotides in glomeruli of rat renal cortex
SUDHIR V. SHAH, THOMAS E. NORTHRUP, YVONNE S. F. Hui, and THOMAS P. DOUSA
Nephrology Research Laboratories, Department of Internal Medicine, Division of Nephrology, and the Department of
Physiology and Biophysics, Mayo Clinic and Foundation, Rochester, Minnesota
Action of serotonin (5-hydroxytryptamine) on cyclic nucleotides
in glomeruli of rat renal cortex. Serotonin (5-hydroxytryptamine)
is known to influence glomerular function and may have an im-
portant role in the pathogenesis of glomerulopathies. Because
serotonin acts in nonrenal tissues through mediation of cyclic
nucleotides, we investigated in vitro its effect on cAMP and cy-
clic guanosine monophosphate (cGMP) in tissue slices and isolat-
ed glomeruli from rat kidney. Serotonin increased cAMP 161
35% but not cGMP in renal cortex; it had no effect on cyclic
nucleotides in medulla and papilla. In isolated glomeruli, sero-
tonin elicited a dose-dependent (in the range of l0- to l0- M)
increase in cAMP; the maximum increase over basal values was
376 45%. Serotonin increased cAMP either in the presence or
in the absence of a cAMP phosphodiesterase inhibitor. In tubular
fraction, serotonin elevated cAMP to a much lesser degree (82
15%). Neither in glomeruli nor in tubules did cGMP concentra-
tions change in response to serotonin, but carbamylcholine, a
known cGMP agonist, significantly increased cGMP concentra-
tions. The increase in cAMP in response to serotonin was
blocked (>85% inhibition) by equimolar concentrations of sero-
tonin antagonists methysergide and cinansenne. Results of this
study demonstrate that interaction of serotonin with receptors in
the kidney, particularly in the glomeruli, cause a striking in-
crease in cAMP concentrations without detectable changes in
cGMP concentrations. These findings suggest that serotonin, ei-
ther synthesized in the kidney or released locally from platelets
aggregated in glomeruli (for example, in association with immu-
nopathologic injury) may exert or modulate its physiologic or
pathologic effects via mediation of cAMP.
Action de Ia serotonine (5-hydroxytryptamine) sur les nucléo-
tides cycliques des glomerules dii cortex renal du rat. Ii est connu
que Ia sérotonine (5-hydroxytryptamine) influence Ia fonction
glomërulaire et peut avoir un rOle important dans Ia pathogënie
des glomérulopathies. Puisque la sérotonine agit sur d'autres tis-
sus que Ic rein par l'intermédiaire des nucléotides cycliques,
nous avons etudi son effet in vitro sur le contenu en cAMP et
cGMP des tranches de rein et des glomérules isolés du rein de
rat. La sérotonine augmente cAMP 161 35%, mais pas cGMP
du cortex renal. Elle n'a pas d'effet sur les nucléotides cycliques
de Ia médullaire et de Ia papille. Dans les glomerules isolés Ia
sérontonine determine une augmentation de cAMP dose dépen-
dante (de l0- a 1O M), l'augmentation maximale est de 376
45% par rapport a Ia valeur basale. La sérotonine augmente
cAMP aussi bien en presence qu'en l'absence d'inhibiteur de la
cAMP phosphodiesterase. Dans les fractions tubulaires la sé-
rotonine n'augmente cAMP qu'à un moindre degre (82 15%).
La sérotonine n'augmente cGMP ni dans les gloméi-ules ni dans
les tubules mais la carbamyicholine, un agoniste connu de cGMP
augmente celui-ci significativement. L'augmentation de cAMP
en réponse a Ia sérotonine est bloquee (inhibition supérieure a
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85%) par des concentrations equimolaires des antagonistes
méthysergide et cinansérine. Les résultats de cc travail demon-
trent que l'interaction de Ia sérotonine avec les récepteurs ré-
naux, particulièrement glomerulaires, determine une augmenta-
tion importante de cAMP sans modification detectable de cGMP.
Ces constatations suggérent que la sérotonine, qu'elle soit syn-
thétisée dans le rein ou libérée localement par des aggrégats
plaquettaires formés dans les glomerules (c'est a dire en associa-
tion avec une lesion immunopathologique), peut exercer ou mod-
uler ses effets physiologiques ou pathologiques par l'inter-
médiaire de cAMP.
The kidney is one of the tissues with the highest
capacity for synthesis and degradation of serotonin
(5-hydroxytryptamine) [1], and the kidney has a
high content of both serotonin [2] and the serotonin
precursor 5-hydroxytryptophan [2]. Serotonin was
shown to have a profound effect on different renal
functional parameters [1]. Administered through
different routes or infused directly into the renal ar-
tery, serotonin caused renal vasoconstriction,
mainly in the cortex, decreased GFR [1, 3], and al-
teration of renal handling of fluid and electrolytes,
mainly decreases in urine flow and sodium excre-
tion [1]. Serotonin was also reported to stimulate
erythropoietin production in the kidney [4].
Perhaps much more important, both experimen-
tal and clinical observations suggest that serotonin
may be a significant factor in the pathogenesis of
major renal disorders, such as glomerulonephritis
or other nephropathies [1]. There is increasing evi-
dence that platelets, a major source (>95%)of cir-
culating blood serotonin [5], participate in the de-
velopment of local glomerular injury occurring in
immune complex glomerulonephritis [6] and also in
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other glomerulopathies, such as those associated
with intravascular coagulation [7]. Serotonin could
be released from platelets which are activated local-
ly in glomeruli and contribute to inflammatory
mechanisms. That the platelet serotonin concentra-
tions were lower in patients with lupus erythema-
tosis nephritis was noted recently [81; in several
glomerulopathies mediated by circulating immune
complexes, high concentrations of plasma serotonin
and low concentrations of platelet serotonin were
reported [9].
In spite of the potential importance of serotonin
in renal pathophysiology, very little is known about
its precise site of action in the kidney and about the
cellular mechanism by which serotonin elicits its ef-
fects in renal tissue.
In some nonrenal tissues, serotonin has been
shown to stimulate formation of cyclic nucleotides,
either cyclic 3'5'-AMP (cAMP) or cyclic 3'5'-GMP
(cGMP), or both, suggesting that these cyclic nil-
cleotides could play a role of "second messen-
gers" in serotonin actions. In mammalian brain tis-
sue [10, 11] or in vascular endothelial cell line [12],
and also in some nonmammalian tissues, such as
moluscan myocardium [13], insect salivary gland
[14], or in liver fluke [15], serotonin increases
cAMP concentrations, or it stimulates adenylate cy-
clase, or it does both. On the other hand, in mam-
malian umbilical artery [16], uterine [17] or bron-
chial [18] smooth muscle, or in monocytes [19] and
platelets [20], serotonin has been shown to cause an
accumulation of cGMP without changes in the
cAMP concentrations. Nevertheless, it is not known
whether serotonin may act on cyclic nucleotides in
kidney tissue.
In view of these considerations, we examined the
serotonin effect on concentrations of cAMP and
cGMP in tissue slices from rat kidney cortex, me-
dulla, and papilla, as well as in glomeruli and tu-
bules isolated from rat renal cortex. Our results
show that, in vitro, serotonin increases cAMP con-
centrations in renal cortical slices and elicits a strik-
ing accumulation of cAMP in isolated glomeruli
without changing the cGMP concentration, but it
has no detectable effect on cyclic nucleotides in the
medulla and papilla.
Methods
Isolation of glomeruli. Tissues samples were ob-
tained from adult male Sprague-Dawley rats. Each
rat, weighing 200 to 250 g, was maintained on an ad
lib standard diet (Purina Laboratory Rat Chow, Ral-
ston Purina Co., St. Louis, Missouri) and tap water.
After inducing anesthesia with pentobarbital (50
mg/kg of body weight), we inserted a polyethylene
catheter (PE-100) into the lower abdominal aorta
immediately above the bifurcation. Subsequently,
the aorta was clamped above the renal arteries, the
renal veins were cut, and the kidneys perfused with
60 to 80 ml of modified Krebs-Ringer phosphate buf-
fer (KRB) of the following composition: 140 mM so-
dium chloride, 5 m potassium chloride, 1.2 mM
magnesium sulfate, 2.0 m calcium chloride, 10 mrvi
glucose, 10 mrvi sodium acetate, 2 m sodium phos-
phate, and 20 mrvi Tris (pH, 7.4). The interval be-
tween clamping the aorta and onset of the perfusion
did not exceed 20 sec. After the kidney surfaces
were completely blanched, the kidneys were re-
moved and placed on an ice-cooled dissecting table.
All subsequent preparative steps were performed at
4°C.
Cortical tissues from the kidneys of two to three
rats were pooled for one experiment. The cortex was
dissected from the kidney and used for preparation
of glomeruli and tubule samples. In experiments
with tissue slices, the kidney was first carefully di-
vided into cortex, medulla, and papilla, and tissue
slices (0.5-mm thick) from these three zones were
cut with a Stadie-Riggs tissue slicer [21, 22]. These
tissue slices were washed several times in ice-cold
KRB. Glomeruli and tubule samples were prepared
with a combination of sieving and differential centri-
fugation. The cortical tissue was minced, strained
through a stainless steel sieve (220-gm opening), and
subsequently passed through a hypodermic needle
(23 gauge, Sherwood Med. Industries). The result-
ing suspension of cortical tissue was washed four
times in KRB by repeated centrifugation at x200g
for 2 mm to eliminate debris of small fragments
floating in the supernatant. The resulting pellet was
resuspended in about 50 ml of KRB and passed
three to five times by x ig gravity filtration sequen-
tially through each of the three nylon sieves (NI-
TEX) with pore-opening sizes of first 390 jim, then
250 j.m, and finally 213 j.m. The particles retained
on the 250-jtm sieve consisted of tubular fragments
and were collected as a tubular fraction. This tubu-
lar fraction, referred to later in the text as "tu-
bules," was washed again on the 250-pm nylon
screen with about 60 to 80 ml of KRB to reduce
glomerular contamination to a negligible level. To
obtain the glomerular fraction, referred to further as
"glomeruli," after filtering through a 213-sm sieve,
we passed the resulting suspension through a screen
cloth (NITEX #25, about 60-jim pore opening); this
step allowed debris and small fragments to pass
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through, with glomeruli retained on the cloth. The
retained glomeruli were recovered by inverting the
screen over a glass beaker and by washing the
glomeruli out with KRB.
Both glomerular and tubular preparations were
then pelleted by centrifugation at x 1 500g for 5 mm.
Pelleted fractions were gently resuspended in 4 ml
of KRB, transferred in preweighed polyallomer
tubes, and centrifuged at x 1500g for 5 mm; the su-
pernatant was removed by aspiration, and the tubes
were weighed again to determine approximate wet
weight of the preparations. Glomeruli or tubules
were suspended in fresh KRB so that approximately
4 to 6 mg (wet weight) of glomeruli and 8 to 12 mg
(wet weight) of tubules were contained in 100 d of
KRB suspension.
The purity of each glomerular suspension was
evaluated by light microscopy and counting of
glomeruli. An aliquot of glomerular suspension (50
to 100 pi) was mixed on the microscopic slide (10:1,
volume per volume) with 0.1% toluidine blue solu-
tion in isotonic saline to visualize cellular elements
and was examined under higher magnification
(x430) to evaluate first the structure of isolated gb-
meruli and then at the lower magnification (x 100) to
determine the glomerular count of suspension. Iso-
lated glomeruli were without capsules, and the
structure was well preserved. The purity of gbomer-
uli was determined by counting at least 200 particles
stained with toluidine blue, and only preparations
which contained more than 95% of glomeruli were
used for subsequent experiments. Tubular suspen-
sion was checked for absence of glomeruli. Gbomer-
uli were also examined microscopically after fixing
in 10% formol and staining with hematoxylin-eosin.
This examination confirmed the intact structure of
glomerular preparations. Criteria for purity of
glomeruli were the same as those used in our other
studies [21, 22].
Glomeruli prepared with this procedure were
morphologically indistinguishable from prepara-
tions obtained by the Ficoll density centrifugation
method, used in our previous experiments [21, 22].
Nevertheless, the degree of purity required for ex-
periments (see above) was obtained more frequent-
ly with this sieving method than it was with the den-
sity centrifugation method [21], and also the yield of
glomeruli was considerably higher. Tubular fraction
obtained with this sieving method was composed of
shorter tubular fragments than that obtained with
the density gradient method [21, 22]. Glomeruli and
tubules prepared by the sieving method showed re-
sponsiveness (in terms of changes in cyclic nude-
otides) to hormonal agents (histamine, parathyroid
hormone, carbamylcholine) analogous to glomeruli
and tubules prepared by the density gradient meth-
od [22].
Incubations and assays. Incubations of tissue
preparations and analyses of cyclic nucleotides
were conducted with only minor modifications to
the method used in our previous study [22]. Freshly
prepared glomeruli (4 to 6 mg, wet weight) and tu-
bules (8 to 12 mg wet weight) were resuspended in
100 j.d of ice-cold KRB. In other experiments, cor-
tical, medullary, and papillary tissue slices (10 to 20
mg wet weight) also were suspended in 100-jd ali-
quots of cold KRB. The tissue slices or suspensions
were distributed randomly into 10-ml glass homoge-
nizer tubes (size A, Thomas Scientific Products,
Philadelphia, Pennsylvania) kept in crushed ice at 00
C, with 300 d of KRB having been added to these
tubes. These suspensions were first preincubated at
37° C for 20 mm in a Dubnoff shaking water bath
(120 cycles/mm). At the end of the 20-mm pre-
incubation period, 50 1.d of 5 mrvi 1-methyl-3-isobu-
tyl xanthine (MIX) dissolved in KRB and either 50
pi of KRB (controls) or hormones and/or drugs dis-
solved in 50 1.d of KRB were added to the various
suspensions. These additions were made within an
interval of 6 sec. The final volume of each suspen-
sion then was 500 1.d of KRB with 0.5 mrvi MIX and
the final concentration of various test agents as in-
dicated in the Results section. Stock solutions of
hormones or drugs were kept at either —20° C or 00
C as appropriate; dilutions and pH adjustments
were made immediately prior to incubation. After
the various test agents and MIX were added, the
tubes were incubated for an additional 2 mm at 37° C
in a metabolic shaking water bath. The incubation
was terminated by adding 500 il of ice-cold 10%
trichloroacetic acid (TCA) to it and homogenizing it
immediately with a Teflon pestle (10 strokes). From
the TCA homogenate a small aliquot (20 d in dupli-
cate) was taken for the determination of protein.
The remainder of the TCA homogenate was divided
into two equal aliguots for determination of cAMP
and cGMP by radioimmunoassay (RIA). Tracer
amounts of tritiated cAMP or tritiated cGMP were
added to the respective aliquots for monitoring re-
covery. Precipitated proteins were removed by cen-
trifugation. TCA was removed from the supernatant
by repeated extraction (x4) with ethyl ether; rem-
nants of ether were evaporated by heating, and
samples were adjusted to neutral pH with 0.5 N so-
dium hydroxide. Aliquots of extracts were used for
determinations of cyclic nucleotides by RIA and for
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measurements of recovery. In preliminary experi-
ments, cAMP and cGMP were separated prior to
RIA on formate DOWEX-! columns according to
the method of Murad, Manganiello, and Vaughan
[23]. Results analogous to other tissue systems [18,
24] were obtained with or without DOWEX-1 col-
umn separation, even when the extracts of the same
tissue sample were measured simultaneously.
Therefore, because of the small quantity of materi-
al, extracts were not routinely passed through
DOWEX-l columns prior to cAMP and cGMP
determinations by RIA.
Cyclic nucleotides were determined by the RIA
originally developed by Steiner, Parker, and Kipnis
[25] and modified, to increase the sensitivity, by
Harper and Brooker [26] and by Frandsen and
Krishna [27]. Samples of tissue extracts and stan-
dards for determination of cAMP were acetylated
[26], and samples for determination of cGMP were
succinylated [27] as described in the original meth-
ods [26, 27].
Acetylated or succinylated samples were in-
cubated in 50 m sodium acetate buffer (pH, 6.2)
with anti-cAMP or anti-cGMP antibodies and 12j
succinyl cAMP methyl ester or with 1251..succinyl
cGMP methyl ester for 16 to 24 hours at 40 C, and
then the free and bound antigens were separated by
ammonium sulphate precipitation [25]. Radio-
activity of the samples was counted in a gamma
counter (Searle Analytical Gamma Counter, model
1285). Specificity and sensitivity of antibodies were
examined in preliminary experiments and were
found to be within the limits claimed by the manu-
facturer (Schwartz-Mann Labs., Orangeburg, New
York). Also, the increase in sensitivity by acetyla-
tion or by succinylation was in agreement with that
reported by the authors [26, 27]. With acetylation
and succinylation of the standards and samples, the
lower limit of sensitivity of RIA was 1 fmole for
both cAMP and cGMP. In the absence of added cold
cAMP or cGMP, approximately 50 to 60% of la-
beled antigen was bound to antibodies. Because
RIA measurements were done on extracts in which
cAMP and cGMP were not separated, the cross-re-
activity of RIA for cAMP and cGMP was tested.
Succinylated cAMP, even at a concentration 100
times higher, did not interfere with measurements
of succinylated cGMP in RIA for cGMP; and con-
versely, acetylated cGMP, even in a concentration
100 times higher than that of acetylated cAMP, did
not interfere with the determination of acetylated
cAMP by RIA for cAMP. The validity of cAMP and
cGMP measurements by RIA was verified also by
the linearity of sample dilutions, by cAMP and
cGMP hydrolysis with cyclic nucleotide phospho-
diesterase, and by quantitative recovery of added
unlabeled cyclic nucleotide to the extracts.
Drug agonists and antagonists used in the present
system were tested for interference with cAMP and
cGMP determination by RIA. None of the tested
agents at concentrations higher than the highest
concentrations used in the incubation mixtures in-
terfered with determination of cAMP or cGMP by
RIA, or with acetylation or succinylation proce-
dures.
Radioactivity of tritiated tracer nucleotides was
determined by liquid scintillation counting. The
quantity of tritiated cAMP and tritiated cGMP trac-
ers for recovery measurements which contributed
to the final concentration of cyclic nucleotides
was calculated and subtracted from each sample.
After correction for recovery and after substraction
of the added radioactive tracer, the contents of
cAMP and cGMP in samples were expressed as
picomoles per milligram of protein. In preliminary
experiments, we established that total protein in
glomerular suspension was linearly proportional to
the number of glomeruli in aliquots of samples in
which glomeruli were counted under the light mi-
croscope.
Because glomeruli, tubules, or slices were ho-
mogenized together with the incubation medium,
the content of cAMP and cGMP represents a sum of
the cyclic nucleotides contained within cells and
that which leaked into the incubation medium. Ac-
curate separation of glomeruli from the medium
would result in a prohibitive time delay between the
end of the incubation and the inactivation of the en-
zymes by homogenization in TCA. Likewise, the
small sample size would make determination of wet
weight in the final incubation inaccurate. The con-
tent of cyclic nucleotide was expressed in pico-
moles per milligram of protein in the incubation
mixture, which was measured in aliquots of the
same TCA-homogenate in which cyclic nucleotides
were measured.
The protein contents were determined in aliquots
of TCA homogenate after neutralization with so-
dium hydroxide by the method of Lowry et al [28],
as used in our previous studies [21, 22]. Determina-
tions of cyclic nucleotides by RIA, protein determi-
nation, and measurements of recovery were run in
duplicate or triplicate.
Glomeruli, tubules, or slices from the same pool
of kidneys were incubated on the same day under
exactly the same conditions with or without added
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Fig. 1. Effect of various concentrations of serotonin on cAMP
content in glomeruli (—.—.—) and in tubules (—L—L—) in
presence of 0.5 ,imi MIX. For experimental details see Methods.
Each point represents the mean SCM of measurements in-
dicated in parentheses.
hormones or drugs. Samples were processed also
(extraction, RIA, and protein determination) at the
same time, using the same batch of reagents. This
design minimizes possible day-to-day variation be-
tween assays and preparative procedures and al-
lows paired comparisons. Glomeruli, tubules, or
slices were incubated in duplicate aliquots for each
condition (controls or with added drugs or antago-
nists), and values of duplicates were averaged and
entered as a single value (N) for the purpose of sta-
tistical analysis. An exception is in the results de-
picted in Fig. 1 (dose-response curve for serotonin),
where each value is based on determination in a
single incubation tube.
The effects of drugs and hormones were eval-
uated as a net difference from control, or as relative
(percent change) differences from control, or both,
by Student's t test for paired comparisons; other
statistical evaluations were done with Student's I
test for group comparisons, as indicated in the Re-
sults. Values of P > 0.05 were considered to be
nonsignificant (NS).
Materials. Serotonin (5-hydroxytryptamine
creatinine sulphate), histamine, and carbamyicho-
line and beef heart cyclic nucleotide phosphodieste-
rase were purchased from Sigma Co., St. Louis,
Missouri. Synthetic 1,34-N-terminal tetratriacont-
apeptide of bovine parathyroid hormone (PTH) ac-
tivity, 3800 lU/mg) was purchased from Beckman
Instruments, Bioproducts, Spinco Division, Palo
Alto, California; and 1-methyl-3-isobutyl-xanthine
(MIX), from Aldrich Chemical Co., Milwaukee,
Wisconsin. Methysergide maleate was a gift from
Sandoz Pharmaceuticals, Hanover, New Jersey;
cinanserine hydrochloride, a gift from Squibb and
Sons, Inc., Princeton, New Jersey; and metiamide,
a gift from Dr. Mendelson, Smith, Kline & French,
Co., Philadelphia, Pennsylvania. [8-Arginine]-vaso-
pressin (AVP; 385 U/mg) was purchased from Cal-
biochem, San Diego, California. Nylon meshes for
sieving were purchased from Nytex Co., Niles, Illi-
nois, catalog numbers HC3-390 (390-pm pore open-
ing), HC 3-250 (25O-Mm pore opening), HC 3-212
(212-tm pore opening), and NITEX #25 (pore
opening, about 60 .tm). Other chemicals, all of the
highest purity grades, were purchased from standard
suppliers. Tritiated cAMP and tritiated cGMP for
measurement of recoveries were purchased from
New England Nuclear, Boston, Massachusetts. Anti-
bodies and 1251-labeled antigens were from RIA kits
for determinations of cAMP and cGMP purchased
from Schwartz-Mann Labs., Orangeburg, New York.
Results
The effect of serotonin on cyclic nucleotides in
slices from the three major kidney zones was exam-
ined first. The results, summarized in Table 1, show
that serotonin increased the cAMP concentration in
slices from renal cortex, but under the same condi-
tions, serotonin had no significant effect on cAMP
in slices from medulla or papilla of the same kid-
ney. In the same experiments, 10 M [8-arginine]-
vasopressin (AVP) markedly increased cAMP in
medullary slices over the basal concentration by
143 28% (mean SEM, N=4; P <0.02, paired I
test), as well as in papillary slices by 205 36%
(N=4; P < 0.02, paired I test). In none of the three
kidney zones did serotonin influence tissue concen-
trations of cGMP. But, 10 M carbamylcholine, a
known stimulant of renal cortical cGMP system [22,
29], elevated the cGMP level by a concentration of
150 35% (N =6; P <0.01, paired t test) as antici-
pated.
In our previous studies, we observed that hormon-
al agents which cause cyclic nucleotide changes in
renal cortical slices can influence differently the
concentrations of cAMP or cGMP in glomeruli and
tubules [22]. Therefore, the effect of serotonin on
cAMP and cGMP in glomeruli (and for comparison
in tubules) isolated from renal cortex was exam-
ined. As we also noted in our previous studies
[22], control (basal) concentrations of both cAMP
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Table 1. Effect of serotonin on cyclic nucleotides in slices from renal cortex, medulla, and papilaa
N' Control
Serotonin
(104M)
Relative change
from control
%
Cortex
Cyclic AMP,pmoles/mg protein (6) 4.1 0.6 11.0 2.3C +161 35c
Cyclic GMP, pmoleslmg protein (6) 0.26 0.04 0.27 0.03 +13 12
Medulla
Cyclic AMP,pmoles/mgprotein (5) 18.6 3.5 20.4 3.1 +17 19
Cyclic GMP,pmoles/mgprotein (4) 0.79 0.25 0.77 0.28 —8 13
Papilla
Cyclic AMP, pmoles/mg protein (5) 117.9 26.3 97.0 27.0 —20 10
Cyclic GMP,pmoles/mg protein (4) 1.92 0.60 1.83 0.77 —10 12
a Values represent the mean SEM.
N denotes number of experiments.
Values are significantly different from control and/or A% is significant at P <0.05 or higher level of significance (paired t test).
Table 2. Effects of serotonin on cyclic nucleotides in glomeruli and tubu1es
Glomeruli Tubules
Relative change Relative change
Serotonin from control Serotonin from control
Nb Control (104M) % N Control (104M)
Cyclic AMP,pmoleslmgprotein (12) 46.5 9.1 207.1 355e +376 45 (12) 7.2 0.7 12.6 l.2C +82 15C
CyclicGMP,pmoles/mgprotein (12) 4.1 0.9 4.7 0.7 +37 20 (12) 0.44 0.1 0.35 0.06 +18 24
a Values represent the mean SEM.
h N denotes number of experiments.
C Values are significantly different from control (control is without addition of serotonin) and/or % change from control is significant
at P < 0.05 or higher level of significance (paired t test).
The percent increase is significantly (P <0.001; t test) higher than was analogous values in tubules.
and cGMP in glomeruli were, in the present ex-
periments, considerably higher in glomeruli than
they were in tubules (Table 2). Serotonin caused a
striking increase in cAMP accumulation in glomeru-
ii; statistically significant but much smaller increas-
es both in absolute (net increase) and relative (per-
cent increase) terms were observed in tubules
(Table 2). When MIX, a cAMP phosphodiesterase
inhibitor, was not included in the incubation medi-
um, the basal concentration of cAMP in incubated
glomeruli was much lower (Table 3) than it was with
0.5 mM MIX (Table 2). Nevertheless, even in the
absence of MIX, serotonin elicited a marked cAMP
increase, and the relative cAMP increase (percent
change) was comparable to that observed when 0.5
mM MIX was included (Table 3).
Serotonin had no effect on cGMP either in gb-
meruli or in tubules. In the same experiments, PTH
(20 gIml) increased markedly tubular cAMP by 838
264% (mean SEM, N = 5; P <0.025, pairedt
test).
In the same preparation of glomeruli in which
serotonin did not change cGMP concentrations,
l0 M carbamylcholine increased cGMP by 154
35% (mean SEM, N = 7, P <0.005, paired t test),
and likewise l0 M histamine caused smaller, but
consistent, cGMP elevation by 105 36% (mean
SEM, N = 6, P <0.05, paired t test). Carbamylcho-
line also increased cGMP in tubules by 110 23%
(mean SEM, N = 5, P < 0.01, paired t test) as
observed in our previous experiments [22].
As depicted in Fig. 1, the increase in cAMP in
glomeruli by serotonin was dose dependent in the
range of 10 to 10' M. The maximal stimulation
occurred in a concentration of l0- to l0 M, and a
half-maximal increase was elicited by about 3 X
10 M serotonin. At the highest concentration of
serotonin tested (l0 M), the stimulatory effect de-
creased. In tubular preparations, a minor cAMP in-
crease occurred at 10 M serotonin. In the tested
range of serotonin concentrations (b0— to 10 M),
no changes in cGMP accumulation either in glome-
ruli or in tubules were observed. Serotonin antago-
nists, either methysergide or cinanserine alone in a
concentration of 10 M, did not change cAMP con-
centrations in glomeruli. Both drugs blocked (more
than 85% inhibition) cAMP accumulation in glomer-
uli (Table 4) elicited by an equimolar concentration
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Table 3. Effect of serotonin on cAMP in glomeruli in the absence of cAMP phosphodiesterase inhibitora
Relative change
Serotonin from control
N' Control (10 M) %
CyclicAMP,pmoles/mg protein (5) 5.6 1.9 25.1 8.9e +352 47'
a Glomeruli were incubated without (control) or with added serotonin as described in the Methods, except that 0.5 mai MIX was not
included in the incubation mixture. Values represent the mean SCM.
N denotes number of experiments.
Values are significantly different from control (without addition of serotonin) andlor z% change from control is significant at P <0.05
or higher level of significance (paired t test).
Table 4. Effects of antagonists on serotonin and histamine stimulation of cAMP in glomeruli
Additionsa
Increase in
cAMPb
pmoleslmg protein
Relative
inhibition'%
Serotonin(N = 7) +260.1 47.8"
Serotonin + methysergide(N=7) + 15.0 8.1 —94 4"
Serotonin (N = 6) +253.8 528d
Serontonin +cinanserine(N = 6) + 36.4 16.1 —87 7"
Serotonin (N = 5) +247.5 642"
Serotonin + metiamide (N =5) +116.3' 285d —46 13d
Histamine (N = 6) +221.0 45.3"
Histamine + methysergide (N = 6) + 120.2 26.7" —40 10"
Histamine (N = 6) +221.0 453d
Histamine + cinanserine(N = 6) +101.0 26.9" —44 16"
Histamine (N = 4) +199.1 39.78
Histamine + metiamide (N = 4) + 7.4 4.48 —93 3"
a Both agonists (serotonin, histamine) and antagonists (cinanserine, methysergide, or metiamide) were added in final concentration,
10 M, in all incubations. N denotes number of experiments. All values represent the mean SCM.
b Increase in glomerular cAMP is above control levels (without addition of drugs; the mean control cAMP level was 54.2 10.4
pmoles/mg protein).
Relative inhibition is expressed as percent decrease from effect of agonist (serotonin or histamine) alone. Inhibition of serotonin with
metiamide is significantly (P < 0.05 or better, t test) lower than is inhibition with methysergide or with cinanserine. Inhibition of hista-
mine with methysergide or with cinanserine is significantly (P < 0.05 or better) lower than it is with metiamide.
"Increases or extent of inhibition is significant at P < 0.05 or higher level of significance (paired t test).
of serotonin. They did not prevent, however, but
only partially reduced the cAMP accumulation elic-
ited by histamine (Table 4). Conversely, metiamide
(an H2-histamine receptor antagonist) did not pre-
vent, it only diminished, in part, the accumulation of
cAMP in response to serotonin, whereas it com-
pletely blocked the stimulatory effect of histamine
(Table 4).
Discussion
The results of this study provide evidence that
serotonin acts on the kidney cortex, and particular-
lyon glomeruli, to increase cellular levels of cAMP.
Because no prior information existed to indicate
whether serotonin would influence renal cyclic nu-
cleotide metabolism in kidney at all, and because in
some nonrenal tissues serotonin was reported to in-
crease cAMP [10—15], and in other tissue types to
increase selectively only cGMP [16—20], present ex-
perimental conditions were aimed to optimize de-
tection of serotonin's effect on renal cyclic nude-
otides in either direction. The short (2 mm) in-
cubation period was used to detect not only changes
in cAMP but also changes in cGMP, which are usu-
ally transient, with early peak and subsequent de-
cline [16, 29]. Moreover, a shorter incubation time
diminishes the possibility of inactivation of tested
agents by the incubated tissues. In control experi-
ments (data not shown here), we found that the pat-
terns of responses to serotonin were analogous also
in 5-mm and 15-mm incubation periods. Inclusion of
0.5 m MIX inhibits both cAMP and cGMP catabo-
lism to about the same degree [21, 30] but not com-
pletely [31] and thus optimizes conditions to ob-
serve increases in cyclic nucleotide concentrations;
but, it also permits detection of decreases in cyclic
nucleotides, in response to hormonal agents. In our
previous study on the glomerular cyclic nucleotide
system, both increases (for example, those elicited
by histamine, carbamylcholine, and PTH) or de-
creases (for example, those elicited by angiotensin
II) were observed [22]. As shown in Table 3, basal
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concentrations of cAMP in glomertili in the absence
of MIX are lower, but the stimulatory effect of sero-
tonin is readily detected. High specificity of anti-
cAMP and anti-cGMP antibodies allows simultane-
ous measurements of both cyclic nucleotides in the
same tissue extracts, excluding errors due to cross-
reactivity.
From the three major anatomic zones of the kid-
ney, serotonin increases cAMP only in cortical
slices (Table 1). Lack of a serotonin effect on cyclic
nucleotides in the medulla and papilla is unlikely to
be due to general unresponsiveness of these prepa-
rations to hormones, because cAMP increased pre-
dictably in response to AVP in the same experi-
ments. Thus, these comparisons suggest that sero-
tonin receptors associated with cyclic nucleotide
generating systems are either absent in rat renal me-
dulla and papilla or that, unlike in cortex, they are
undetectable under present conditions. Since carba-
myicholine increases cGMP in cortical slices, a
general unresponsiveness of the cGMP system to
hormonal agents does not seem to explain the lack
of a serotonin effect. Because tissue slices were pre-
pared from kidneys thoroughly perfused to remove
blood, the increase of cAMP in response to sero-
tonin is most likely due to an interaction of this
agent with receptors in renal cortical tissue.
Inasmuch as hormonal agents could act dif-
ferently on glomerular and tubular components of
the kidney cortex [22], the effect of serotonin was
studied further in isolated glomeruli and tubules.
The striking cAMP increase in glomeruli in re-
sponse to serotonin (Table 2) indicates that these
subunits of nephrons are particularly rich in sero-
tonin receptors associated with the cAMP gener-
ating system. This conclusion is emphasized com-
paring it with the data on tubules or unfractionated
cortical slices where much smaller responses in
cAMP were observed under the identical incubation
conditions.
With respect to findings in tubules, it should be
stressed that whereas glomeruli are a homoge-
nous, well-defined preparation, tubular fraction, as
studied in our experiments, is a rather hetero-
genous mixture of tubular fragments from diverse
nephron segments, all present in the cortex. Keep-
ing this possible limitation in mind, and considering
also the small responses in cortical slices, we think
the finding of a small cAMP response to serotonin in
tubules may indicate that tubules contain few sero-
tonin receptors associated with the cAMP-gen-
erating system, namely when compared with gb-
meruli (Table 2). Alternatively, a serotonin-sensitive
cAMP system in tubules might be localized in a
very limited subsegment of tubular system, as it
is the case of adenylate cyclase sensitive to f3-
adrenergic agents [32]. Finally, a small admixture of
cells from interstitium or vasculature in the tubular
fraction cannot be completely ruled out. Never-
theless, responsiveness of the present tubular prep-
aration to hormones in general is evidenced by the
many-fold cAMP increase by PTH, and cGMP stim-
ulation by carbamylcholine.
Serotonin not only caused a several-fold increase
in glomerular cAMP at maximal stimulatory doses
(lO to lO M), but the molar concentrations of
serotonin required for half-maximum stimulation (3
x lO M) seem to lower even that of histamine [22],
suggesting high affinity of gbomerular receptors for
serotonin. Observation that the serotonin antago-
nists methysergide and cinanserine [33] blocked
completely stimulation of glomerular cAMP by sero-
tonin, but only in part reduced cAMP stimulation
by histamine, suggests indirectly that serotonin acts
in gbomeruli on sites different from the H2-histamine
receptor (Table 4). This notion is further supported
by the finding that metiamide, an H2-histamine re-
ceptor antagonist [34], completely blocked the ef-
fect of histamine (Table 4) [22] and only partially
blunted the response to serotonin (Table 4). It is not
surprising that the specificity of inhibition of hor-
monal responses in glomerular cAMP by anti-
serotonin drugs and the H2-blocking agent is not ab-
solute. The serotonin antagonists methysergide and
cinanserine are known from other tissue systems
to inhibit, in addition to their well-known anti-
serotonin effects, to a various degree also action of
other biogenic amines [33]. It also was reported re-
cently that derivatives of D-lysergic acid, a potent
serotonin antagonist, strongly inhibit an H2-recep-
tor-associated brain adenylate cyclase [35]. Me-
tiamide in higher concentrations may have a non-
specific inhibitory effect on adenylate cyclase [361;
some common structural characteristics of D-lyser-
gic acid and H2-antihistaminics [35]also suggest the
possible interaction of metiamide with serotonin re-
ceptors in glomeruli. In any case, this partial cross-
reactivity of serotonin blocking agents and H2-anti-
histaminics should be taken into consideration in
the interpretation of studies in vivo, when the above-
mentioned or analogous antagonistic drugs are used
as experimental tools to block the effects of endoge-
nous serotonin and histamine on the kidney. Sero-
tonin differs from histamine in its effect on glomeru-
ii also in another aspect: unlike histamine, serotonin
selectively stimulates cAMP without detectable in-
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fluence on cGMP. This lack of cGMP response oc-
curs in the same preparations of glomeruli in which
histamine and carbamyicholine elevate cGMP.
It remains to be analyzed with use of other
methodologies in which cell types in glomeruli
serotonin increases cAMP. In nonrenal tissues,
serotonin was reported to increase selectively
cGMP but not cAMP in cells with prominent con-
tractile function [16-18] and to increase cAMP in
intimal endothelial [12] and epithelial [14] cell ele-
ments. Such a comparison may surmise, indirectly,
that serotonin could act primarily on endothelial
and epithelial cell types also in glomeruli.
Possible pathophysiologic implications of the
present findings should be considered at least brief-
ly. First, serotonin's interaction with glomeruli,
which leads to an increase in cAMP, may be related
to the effects of serotonin on glomerular dynamics,
such as decrease in GFR [1, 3]. Even more relevant
could be serotonin's role as it is released locally
from activated platelets in the pathogenesis of
glomerulopathies [6-8]. Inflammatory responses to
acute immune injury were shown to be modulated
by cAMP in several model systems [37—39]. It is
conceivable that serotonin released locally in
glomeruli from platelets, for example, in immune-
complex-mediated glomerulopathies [6-8], could
act, through cAMP mediation, to influence the gb-
merular inflammation. Serotonin in low (10 to 10
M) concentrations was shown to stimulate fibroblast
proliferation, biosynthesis and maturation of colla-
gen [40]; cAMP was reported to stimulate [41, 42]
and/or modulate directionality [43] of collagen bio-
synthesis. Thus, the sustained high local concentra-
tions of serotonin, originated from platelet aggre-
gates or microthrombi in glomeruli, could be an im-
portant factor in the development of basement
membrane thickening or other sclerosing processes
in glomeruli.
It would be premature to make, from the present
observations, far-reaching conclusions about
cAMP-mediated renal effects of serotonin. Never-
theless, our findings, which demonstrate the pres-
ence of a serotonin-sensitive cAMP generating sys-
tem in glomeruli, may represent a starting point for
future investigations on serotonin's role in glomeru-
lar pathophysiology.
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